CSL starts program to produce COVID-19 convalescent plasma product in Australia

An Australian ‘convalescent plasma’ product is to be developed by CSL with the aim of using anti-SARS-CoV-2 immunoglobulin to prevent people with COVID-19 from advancing to more severe disease. The investigational product, to be known as COVID-19 Immunoglobulin, will be developed by CSL Behring Australia at its manufacturing facility in Victoria from the plasma of ...

Already a member?

Login to keep reading.

© 2021 the limbic